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Abstract
Rationale The notion that the onset of action of antidepres-
sant drugs (ADs) takes weeks is widely accepted; however,
the sequence of events necessary for therapeutic effects still
remains obscure.
Objective We aimed to evaluate a time-course of ADs-
induced alterations in the expression of 95 selected genes in
4 regions of the rat brain: the prefrontal and cingulate cortices,
the dentate gyrus of the hippocampus, and the amygdala.
Methods We employed RT-PCR array to evaluate changes
during a time-course (1, 3, 7, 14, and 21 days) of treatments
with desipramine (DMI) and citalopram (CIT). In addition to
repeated treatment, we also conducted acute treatment (a single
dose of drug followed by the same time intervals as the
repeated doses).
Results Time-dependent and structure-specific changes in
gene expression patterns allowed us to identify spatiotemporal
differences in the molecular action of two ADs. Singular value
decomposition analysis revealed differences in the global gene
expression profiles between treatment types. The numbers of
characteristic modes were generally smaller after CIT treat-
ment than after DMI treatment. Analysis of the dynamics of
gene expression revealed that the most significant changes
concerned immediate early genes, whose expression was also
visualized by in situ hybridization. Transcription factor bind-
ing site analysis revealed an over-representation of serum
response factor binding sites in the promoters of genes that
changed upon treatment with both ADs.
Conclusions The observed gene expression patterns were
highly dynamic, with oscillations and peaks at various time
points of treatment. Our study also revealed novel potential
targets of antidepressant action, i.e., Dbp and Id1 genes.
Keywords Antidepressant . Desipramine . Citalopram .
Gene expression . RT-PCR . In situ hybridization . Time-
course . Delayed onset of action . Rats
Introduction
Despite the increasing prescription of antidepressant drugs
(ADs) and their intensive investigation for almost five deca-
des, the mechanisms of their antidepressant action remain
unresolved. Some major hypotheses related to depression
include monoamine deficiency (Elhwuegi 2004), abnormali-
ties in the hypothalamus–pituitary–adrenal (HPA) axis, and
the cytokine hypothesis (Leonard and Myint 2009), but the
nature and involvement of these components in the etiology of
depression remains uncertain. In addition to the monoamine
deficiency hypothesis, depression is often associated with the
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sustained hyperactivity of the stress axis caused by the stress
neurotransmitters, corticotrophin-releasing hormone (CRH)
and urocortin, the effects of which are mediated through the
CRHR1 and CRHR2 receptors (Leonard and Myint 2009).
There is also evidence that inflammatory processes play an
important role in depression, and most antidepressants have
anti-inflammatory effects (Leonard and Myint 2009; Maes et
al. 2009). Preclinical and clinical evidence suggest that neuro-
peptides (such as galanin, neuropeptide Y, and proenkephalin)
and their receptors may be directly involved in depression and
related illnesses (Dziedzicka-Wasylewska and Papp 1996;
Dziedzicka-Wasylewska et al. 2002; Kuteeva et al. 2008;
Redrobe et al. 2002).
Based on the above-mentioned data and literature survey
(Boehm et al. 2006; Carr et al. 2010; Drigues et al. 2003;
Frechilla et al. 1998; Orsetti et al. 2008; Urani et al. 2005),
genes of interest that are believed to be crucial in ADs action
were selected for our study. These genes encode receptors
(e.g., Adra, Adrb, Cnr, Drd, GalR, Gria, and Opr), transcrip-
tion factors (e.g., Creb, Crem, Egr, Fos, Jun, Jund, and Sp1),
genes involved in inflammatory responses (e.g., Il10r, Il1r,
Il6r, Stat, and Tnf), HPA activity (e.g.,Crhbp,Crhr, andUcn),
neuronal apoptosis and synaptic plasticity (e.g., Bcl2, Bdnf,
Cacna, Cdk, Ntf, and Vgf), and a number of other genes
previously unlinked directly to ADs action but important
because of their involvement in the transcriptional machinery
of the cell (e.g., Aes, Arnt, Cebpb, Dbp, Esr2, Ets, Gata2,
Hdac, Id1, Nr, Pax6, and Yy1). In contrast to the vast majority
of preclinical studies, which have been conducted using ani-
mals treated with ADs repeatedly (typically 7–14 days), we
decided to conduct a temporal analysis of the expression of
genes regulated by ADs in specific brain regions.
The notion that the onset of ADs action generally takes
weeks is widely accepted. However, questions concerning the
sequence of molecular events that are necessary for the ther-
apeutic effects to occur during the time following drug admin-
istration remain unanswered. This delay in response suggests
that antidepressant action is a complex multicellular process
that requires the orchestration of many biochemical events,
including changes in the transcription of genes that may not be
directly involved in the neurotransmitter signaling cascade.
Previous studies have shown that delayed onset of ADs action
(e.g., changes in receptor density) is induced not only by
different types of chronic treatments but also by single-dose
antidepressant treatments followed by a certain period of
drug-free time (Dziedzicka-Wasylewska and Rogoz 1997;
Dziedzicka-Wasylewska et al. 2001; Kuśmider et al. 2006,
2007). Therefore, we additionally checked whether a single
dose of a drug followed by a drug-free period induced changes
similar to those observed after repeated AD treatments.
Because the activation of the limbic system is a relatively
consistent biological finding in patients with major depres-
sion (aan het Rot et al. 2009; Hercher et al. 2009; Ressler
and Mayberg 2007; Tanti and Belzung 2010), we focused
our study on the time-dependent effects of ADs on the
expression of selected genes in the limbic regions of the
brain, including the prefrontal cortex (PCX), the cingulate
cortex (CCX), the dentate gyrus of the hippocampus (HIP),
and the basolateral nucleus of the amygdala (AMY).
Therefore, we applied automated laser microdissection,
RNA isolation, and amplification (custom RT-PCR arrays)
to determine the expression level of selected genes and to
investigate the mode of action of the tricyclic antidepressant
desipramine (DMI) and selective serotonin reuptake inhibitor
citalopram (CIT) in the above-mentioned four regions of the
rat brain. The laser microdissection technique allowed the
precise excision of a defined population of cells, and the RT-
PCR arrays allowed the quantification of minute amounts of
transcripts. Additionally, we used an advanced bioinformatics
approach, i.e., singular value decomposition (SVD) represen-
tation of time-dependent multiple gene expression data, which
allowed the comparison of global gene expression patterns
across different brain regions and used ADs. The SVD is an
analytic procedure which has been successfully adopted to
analyze the time dynamics of multiple gene expression data-
sets (Holter et al. 2000; 2001; Simek et al. 2004).
Through the experimental design of our study, we expected
to highlight some unresolved questions regarding the molec-
ular mechanisms of antidepressant action. First, what is the
time-course of antidepressant action, i.e., which molecular
targets are affected by a specific AD and at what time during
treatment does it occur? What are the structure-specific
changes in gene expression that occur during ADs treatment?
Are there common end points of antidepressant action, i.e., do
ADs belonging to different pharmacological classes target a
final common molecular pathway? Finally, does acute treat-
ment followed by a drug-free period of time induce similar
molecular changes to those caused by repeated treatment?
Methods
Animals
Male Wistar rats weighting 250–310 g at the beginning of
the experiments were used. Animals were housed six to
eight per cage under a 12-h dark/light cycle, with food and
water supplied ad libitum. All animal procedures used in
this study were approved by the local Bioethics Commission
at the Institute of Pharmacology, Polish Academy of Scien-
ces (Krakow, Poland).
Drug treatment
DMI and CIT were administered in doses of 15 mg/kg
in a volume of 2 ml i.p. daily, and all animals were
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injected once a day during the 21 consecutive days of
the experiment, either with saline or antidepressant. The
doses of drugs were chosen based on our previous
experience and literature data (Kuśmider et al. 2006,
2007; Finnegan et al. 1987; Nibuya et al. 1995, 1996;
Zhao et al. 2008; Fujimaki et al. 2000; Thome et al.
2000; Castagné et al. 2009). The control groups re-
ceived vehicle (saline) for 21 days, and four groups
were treated repeatedly with the appropriate drug for
21, 14, 7, and 3 days prior to the end of the experi-
ments. There were additional groups treated with a
single dose of AD and sacrificed at the same time
points (i.e., 21, 14, 7, and 3 days) and 1 day afterwards.
The experimental paradigm is presented in Fig. 1a.
Brains were removed 24 h after the last injection, rapidly
frozen in a heptane/dry ice mixture, and kept at −80°C until
preparation.
Tissue collection and RNA isolation
Brains were always sectioned by the same investigator into
50-μm slices using a cryostat (Leica Microsystems GmbH).
Neuroanatomical descriptions are based on the nomenclature
provided by the rat brain atlas (Paxinos and Watson 1998).
Four brain regions were excised with a laser microdissector
(Leica Microsystems GmbH): the PCX, the CCX, the HIP,
and the AMY (for the coronal diagrams and microdissected
areas, see Fig. 1b). A MicroRnase Kit (Qiagen Inc.) was used
to extract total RNA from the microdissected samples. The
total RNA concentration was measured using a NanoDrop
ND-1000 Spectrometer (ThermoScientific Inc.). The quality
of the isolated RNA was checked using a microcapillary
electrophoresis system (BioRad) according to the manufac-
turer’s instructions, and samples that passed the quality thresh-



























Fig. 1 (a) A schema of the
experimental procedures used.
The experiments lasted for a
total of 21 days. The control
groups received saline for
21 days. The repeatedly treated
groups were treated either with
DMI or CIT for 21, 14, 7, or
3 days. The single-dose
treatment groups received drugs
only once during the
experiments at the same time
points (21, 14, 7, and 3 days
and one additional day before
the end of the experiment),
followed by a drug-free period
of time and saline injections.
(b) Drawings of the coronal
diagrams adapted from the rat
brain atlas (Paxinos and Watson
1998) and the microdissected
brain regions in which gene
expression was studied, i.e., the
prefrontal cortex (PCX), the
cingulate cortex (CCX), the
dentate gyrus of the
hippocampus (HIP), the
basolateral nuclei of the
amygdala (AMY)
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Quantitative RT-PCR
mRNA was reverse transcribed with random hexamers to
generate single-stranded cDNA transcripts according to the
manufacturer’s protocol of the High Capacity cDNA Ar-
chive Kit (Applied Biosystems). For qPCR reactions, cDNA
from three individuals was taken for each group. A prede-
signed TaqMan Low Density Array (TLDA) in a 96-well
format (Applied Biosystems) was used, and duplicates were
performed for the expression of each gene in each sample
(for the accession numbers of the probes used, see Supple-
mentary file 1). A total amount of 100 ng of cDNA for each
sample, RNase-free water, and 50 μl of TaqMan Universal
PCR Master Mix were loaded into each reservoir to a total
volume of 100 μl/reservoir. Real-time PCR amplifications
were performed using a 7900 HT Real-Time PCR Sys-
tem (Applied Biosystems). The thermocycling condi-
tions for the reactions were a 10-min initial setup at
95°C, followed by 40 cycles of 30 s denaturation at 97°C
and 1 min annealing/extension at 60°C. The results for
each plate were analyzed using ABI PRISM SDS2.3
(Applied Biosystems) software to calculate the raw
value of Cq (quantification cycle, also known as the
threshold cycle, crossing point, or take-off point) in
each well. 18 S rRNA was used as an endogenous
control, and Rpl32 and Ppia were used as reference
genes. The levels of expressed genes were measured
using a relative quantitative method (Pfaffl 2001), with
the Ppia and Rpl32 genes as reference genes and a
control group (saline treated) as a calibrator (Applied
Biosystems, UserBulletin#2).
Data analysis
Genes whose Cq values were higher than 38 or undetermined
in more than a half of the samples per analyzed brain region
were excluded from analysis (for each structure and each drug,
there were 10 time groups, n06 per group). Statistical analysis
was performed on the list of probes detected in each structure
after each specific drug treatment. All statistical analyses of
the qPCR data used ΔCq values (Cq normalized to endoge-
nous controls), whereas graphs represented the fold change (2
−ΔΔCq) ± SEM. Data were analyzed by two-way analysis of
variance (ANOVA) with the treatment type-specific factor
(single dose or repeated) and time factor. Correction for mul-
tiple testing was applied separately for each of the main factors
from the ANOVA by controlling for the percentage FDR
(Benjamini and Hochberg 1995). ANOVA was followed by
a Bonferroni test as a post hoc analysis to determine where
significant differences occurred. The threshold level for sta-
tistical significance was p<0.05.
Gene ontology analysis
The functional annotation analysis tool DAVID 2008 was
used to identify over-represented gene ontology (GO)
groups among the gene expression profiles and to group
the genes into functional classifications (Huang et al. 2009).
The lists of gene symbols (Entrez IDs), together with a
particular background annotation distribution (sets of genes
for which mRNA levels were detected in each brain struc-
ture), were used as the input files. Over-represented GO
terms (GOTERM_CC_ALL, GOTERM_BP_ALL,
GOTERM_MF_ALL) were defined as having at least three
transcripts and a maximum EASE score of 0.1.
Identification of transcription factor binding sites enriched
in coregulated transcripts
Identification of over-represented transcription factor binding
sites (TFBSs) was performed using the cREMaG database
(Piechota et al. 2010) by submitting Entrez IDs lists of genes
that reached statistical significance for each ANOVA factor.
Functional promoter sequences were identified by carrying
out alignments between the 5′ upstream sequences of orthol-
ogous rat and human genes. The analysis was performed with
the default parameters of a 70 % conservation threshold and a
maximum number of 10 most conserved TFBSs in noncoding
regions between 5,000 bp upstream and 1,000 bp downstream
of the transcriptional start site.
SVD analysis
Data on multiple gene expression at sequential time points
were analyzed using the SVD as a means to capture dominant
trends, called characteristic modes. SVD was performed for
the data, which were prepared as follows: first, the whole
dataset was subjected to ANOVA (Brandt 1997). The aim of
this procedure was to select a set of genes for which the
changes during our experiments were statistically significant.
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In our case, t is the number of time points and n is the
total number of samples for a given time series. Here, we
assumed that, if for a given time series Fc=Ft  1:5 (where
Fc is the value calculated for this time series and Ft is the
theoretical value for the significance level equal to 0.9), it
was considered for further analysis. Next, the filtered time
series were normalized (Stahlberg et al. 2008). This proce-
dure reduces the length of each time series by one, as the
value of the expression without any treatment is used as the
reference value. The value at each other time point is calcu-
lated in accordance with the following formula:
AEi ¼ dEi  dEh iSD ;
where dEi is calculated as dEi ¼ log2 2E0Eið Þ ; E is the
expression at a given time point i; dEh i is the mean; and
SD is the standard deviation of the expression at a given
time point.
Mathematically, SVD means that the n×m matrix A is
represented asA ¼ USVT where U is an n×n matrix; V is an
m×m matrix; and S is an m×m diagonal matrix of eigenval-
ues of matrix A. Our interest lies in the number of positive
eigenvalues, r, on which basis we are able determine the so-


















In the case of a gene expression time series, each row of
matrix A represents the expression profile of one gene and
each column represents the level of expression of each gene
at a given time point. Here, SVD was performed if the
number of genes selected in the ANOVA was greater than
the number of time points, i.e., 5 (1, 3, 7, 14, and 21 days).
The expression profile of any given gene is a linear combi-
nation of the obtained modes with coefficients equal to the
corresponding elements of the matrix U. The contribution of
each mode to the expression profile of each gene can also be
calculated (Simek et al. 2004).
In situ hybridization studies
The brains of animals treated with CIT for 3 days repeatedly
or in single dose and from the control group were stored
at –80°C. The frozen brains were cut into 12-μm slices
using a cryostat (Leica). The following antisense oligonu-
cleotide probes complementary to the mRNAs encoding the
selected genes were used: c-fos, 5′-GCA GCG GGA GGA
TGA CGC CTC GTA GTC CGC GTT GAA ACC CGA
GAA CAT-3′ (Curran et al. 1987); Egr1, 5′-CCG TTG CTC
AGC AGC ATC ATC TCC TCC AGT TTG GGG TAG
TTG TCC-3′ (Milbrandt 1987); Nr4a1, 5′-GGT GGC AGG
TGC GGT GGG CGC CGT CTC GGG GCT GGC CAG
GTC CAT-3′ (Hazel et al. 1988); and Id1, 5′-GCA CTG
CTA CTG GCG ACC TTC ATG ATC CTG AGG ACA
GGC GGA GAG G-3′ (designed and checked for specificity
in BLAST, NCBI). All probes were synthesized by Gen-
omed (Poland) and labeled with [35S]dATP (Hartmann An-
alytic) at the 3′ end using terminal transferase (New England
Biolabs). Following the preincubation, the brain slices were
incubated with hybridization buffer containing the labeled
probes (10,000 CPM/μl) for 18 h at 37°C, then were washed
in 1× SSC solution, three times for 20 min with 2× SSC
containing 50 % formamide (Merck) at 42°C and after that
in 1× SSC (15 min), water (5 min) and rinsed in 70 %
ethanol. The images were obtained using FujiFilm BAS
5000 Phosphoimager and they were analyzed using Fuji-
Film software (Image Gauge, V4.0). The identification of
brain structures was defined according to the rat brain atlas
(Paxinos and Watson 1998). Statistical analysis was carried
out by two-way ANOVA and Student’s t test was used as
post hoc test to compare changes in mRNA level in CCX
between the 3-day-treated rats and control group. A value of
p<0.05 was considered to be significant.
Results
SVD analyses revealed differences in the global gene
expression profiles between treatment types
For each drug and brain region, two time series gene ex-
pression datasets were compared (from the repeated and
single-dose modes of treatment). Time series consisting of
six time points (0, 1, 3, 7, 14, and 21 days of treatment) were
analyzed by SVD. We show that highly complex sets of
gene expression profiles can be represented by a small
number of “characteristic modes” that capture most of the
expression information in the temporal patterns of gene
expression change. Other aspects of the decomposition in-
dicate the extent to which a gene exhibits a pattern similar to
those provided by the singular vectors. Thus, once a set of
interesting patterns has been identified, genes can be ranked
by their relationship with given patterns.
The overall results of the SVD analysis (SVD modes) are
presented in Fig. 2. Distinct modes following repeated and
single-dose treatments were detected. The contribution of
characteristic mode to the expression profile of each gene
was calculated, and genes with the highest contribution to
each mode are listed in Table 1. The number of genes whose
expression profiles were best described by a characteristic
mode were larger for the single-dose treatment. The global
temporal change in gene expression following repeated DMI
treatment in the PCX was dominated by the top four modes,
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whereas that following the single-dose treatment was domi-
nated by the top three modes (Fig. 2a, right part). The mode
sets for the CCX, the HIP, and the AMY are presented in
Fig. 2b–d, right part. These figures revealed a complex pattern
of expression, with oscillations at different time points of
treatment. The temporal patterns of gene expression after
DMI treatment described by the use of modes varied among
the brain regions and between treatment types (repeated and
single dose). However, there were some genes that could be
grouped together (described by a common mode), although
their temporal expression profiles differed between treatment
types (the modes that contributed the most to their expression
have different time-courses). After CIT treatment, the numb-
ers of characteristic modes were generally smaller than after
DMI treatment. No modes could be generated for the PCX
after repeated CIT treatment and for the AMY after repeated
and single-dose CIT treatment because the number of genes
selected in ANOVA for a specific treatment type was smaller
than the number of the time points.
Comparisons between drug and brain regions indicated
multiple time-dependent changes in gene expression
The strategy of a detailed time-course study of gene expres-
sion alterations upon antidepressant treatment was applied
to verify the question whether acute and repeated adminis-
tration of an AD results in similar effects. To analyze the
dynamics of the changes and the influence of the time and
treatment type-specific factors, two-way ANOVA was per-
formed. The genes for which expression changes reached
the level of statistical significance (p<0.05 for each factor
after multiple comparison corrections) are presented in Venn
diagrams in Fig. 2a–h, left part. The ANOVAwas followed
by the analyses of the biological function of the obtained
gene sets by examining over-representation of GO terms and
TFBSs (Table 2).
Functional analyses of genes exhibiting significant
changes during the treatment period and the identification
of transcription factor binding sites
GO terms were identified separately for each dataset (two-way
ANOVA filtered), specific brain region and drug, according to
the observed temporal gene expression changes (p<0.05 for
the time factor after correction for multiple comparisons). The
results for each dataset are presented in Table 2.
To find molecular factors involved in the transcriptional
control of the observed gene expression changes over time, an
in silico method of TFBS identification was used. We ana-
lyzed gene promoters on the assumption that a subset of the
genes with altered expression following a specific treatment
might be coregulated by common transcription factors. For
this purpose, we used the cREMaG database. The results are
presented in Table 2. Surprisingly, the over-representation of
binding sites was similar between brain regions and between
drugs. After DMI treatment, the TFBSs for myocyte enhancer
factor 2 (MEF2A) and serum response factor (SRF) were over-
represented. In addition to SRF and MEF2A, PAX5, ESR2,
FOXF2, and CEBPA factors were also over-represented in
promoters of genes with altered expression in CCX and
CREB1 factor was over-represented in the HIP and AMY.
Following CIT treatment, the over-represented TFBSs partly
overlapped with those identified for DMI treatment in the
same brain regions, with the SRF, MEF2A, and PAX families
of transcription factors being affected in both cases. Interest-
ingly, the CREB1 binding site was over-represented in all
brain structures after CIT treatment.
Dynamics in gene expression at the level of individual genes
The analyses described above revealed the diversity in the
global gene expression profiles depending on the brain
structure and the drug used. Although they provide an
overall view, they give no answer about the time-course of
single, specific genes. We have chosen a subset of genes for
which expression was significantly altered according to two-
way ANOVA. Figure 3 presents the changes in the mRNA
levels of certain transcription factor genes for which the
observed changes were the greatest and were statistically
significant in almost all regions. Interestingly, a high corre-
lation was observed in the expression profiles between Fos
and Nr4a1 and, to a lesser extent, Egr1. In the PCX, CCX,
and AMY, the initial decrease in Fos mRNA was observed,
with the subsequent increase at day 7, compared to the
control level. Differences between the repeated and single-
dose treatments were apparent. Similar changes were ob-
served for Nr4a1 in the PCX and CCX. Significant
Fig. 2 The left parts of the pictures include Venn diagrams comparing
changes in gene expression depending on the drug and the brain
region. Venn diagrams present genes for which changes in expression
reached the level of statistical significance estimated by two-way
ANOVA following FDR correction for multiple comparisons after
DMI (a–d) or CIT (e–h) treatment in the PCX (a, e), the CCX (b, f),
the HIP (c, g), and the AMY (d, h). Genes in circles represent
significant changes in gene expression by each factor (treatment type
and time), as well as their interaction. The complete results of the two-
way ANOVA and p values are presented in Supplementary files 1 and
2. The right part of each picture present comparative SVD analysis of
structure-dependent gene expression following repeated and single-
dose DMI and CIT treatments. The datasets obtained from repeatedly
and acutely treated rats were transformed separately by SVD after DMI
(a–d) and CIT (e–h) treatment for each brain region: the PCX (a, e),
the CCX (b, f), the HIP (c, g), and the AMY (d, h). No modes could be
generated for the PCX after repeated CIT treatment and for the AMY
after repeated and single-dose CIT treatment because the number of
genes selected in ANOVA for a specific treatment type was smaller
than the number of the time points. The genes for which the expression
profiles were most similar to the global SVD mode are listed in Table 1
b
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differences between the repeated and single-dose DMI treat-
ments were also observed for the Dbp and Id1. In the PCX
and CCX, there was an expression peak for Id1 on day 3 in
the PCX and CCX and on day 14 of the repeated treatment
in the HIP and AMY, respectively, while its expression
remained constant under the single-dose treatment. Opposite
changes were observed for theDbp gene for which expression
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Table 1 Genes with expression profiles most closely approximating the SVD modes after treatment with DMI (top) and CIT (bottom) in the PCX,
CCX, HIP, and AMY
Region Treatment Mode Gene symbol
Desipramine
PCX DMI repeated Mode 1 Akr1a1, Bcl2, Cacna1a, Crhbp, Ctcf, Egr1, Gria2, Hdac1, Id1, Jund, Ntrk2,
Penk1, Ppia, Scn2a1, Sst, Stat3, Tparl,Yy1
Mode 2 Adra2a, Cebpb, Cplx2, Dbp, Gria3, Pir
DMI single-dose Mode 1 Adra1d, Adra2a, Arnt, Atp6v0c, Cnr1, Creb1, Crhbp, Crhr1, Ctcf, Egr1,
Gria1, Gria2, Npy, Ppia, S100a10, Sp1, Sst, Tparl, Yy1
Mode 2 Fos
Mode 3 Nr4a1, Penk1
CCX DMI repeated Mode 1 Adrb1, Arrb2, Dbp, Hdac1, Hdac3, Id1, Penk1
Mode 2 Adra2a, Cplx2
DMI single-dose Mode 1 Atp6v0c, Cplx2, Crhbp, Drd1ip, Egr1, Fos, Gria1, Htr2c, Nr4a1, Sst
Mode 2 Adrb1, Arrb2, Hdac1, Penk1
Mode 3 Adra2a, Hdac5
HIP DMI repeated Mode 1 Adra1d, Adrb1, Akr1a1, Arnt, Atp6v0c, Dbp, Egr1, Ets1, Gria2, Hdac3,
Npy2r, Ppia, Stat3
Mode 2 Cacna1a, Fos, Id1, Penk1
Mode 3 Bcl2, Nr4a1
DMI single-dose Mode 1 Adrb1, Atp6v0c, Cdk5, Cplx2, Crhbp, Drd1ip, Egr1, Ets1, Galr2, Gria2,
Gria3, Hdac3, Htr1a, Id3, Il1r1, Jun, Jund, Ndrg2, Npy2r
Mode 2 Akt1, Galr3, Npy
Mode 3 Id1
AMY DMI repeated Mode 1 Adrb1, Aes, Akr1a1, Atp6v0c, Cdk5, Cebpb, Crhbp, Crhr1, Gria1, Gria2,
Gria3, Hdac3, Hdac5, Nr2f2, Ntrk2, Ppia
Mode 2 Akt1, Fos, Nr4a1, Nr4a2, Oprk1
DMI single-dose Mode 1 Adra2c, Adrb1, Aes, Akr1a1, Akt1, Arrb1, Atp6v0c, Bcl2, Bdnf, Cacna1a,
Cdk5, Cnr1, Crhr1, Dbp, Drd1ip, Egr1, Ets1, Fos, Galr1, Gap43, Gria3,
Hdac1, Hdac3, Htr2c, Id1, Il1r1, Il6, Jund, Nr4a1, Ntrk2, Oprk1, Pax6,
Penk1, Pomc, Rxra, S100a10, Scn2a1, Sst, Tparl
Mode 2 Hdac5, Ndrg2, Nr4a2, Ppia
Mode 3 Gria1, Gria2, Id3, Ntf3, Stat5a
Citalopram
PCX CIT single-dose Mode 1 Adrb2, Cdk5, Cnr1, Ets1, Fos, Gap43, Hdac1, Hspb1, Htr2c, Id1, Id3,
Il6ra, Nr4a1, Pax6, Ppia, Rxra, S100a10, Stat1
Mode 2 Cplx1
CCX CIT repeated Mode 1 Egr1, Fos, Nr4a1
Mode 2 Ntf3, S100a10, Stat1
CIT single-dose Mode 1 Adra2c, Arnt, Drd2, Egr1, Ets1, Fos, Galr2, Gata2, Htr2c, Id1, Id3, Jun,
Nr4a1
Mode 2 Arrb2, Drd1ip, Esr2, Grip2
HIP CIT repeated Mode 1 Id3, Ndrg2, Npy, Plat, Pnoc, Ppia, Scn2a1, Stat1, Tparl, Yy1
Mode 2 Arrb2, Galr3
Mode 3 Ets1, Npy2r
CIT single-dose Mode 1 Ets1, Fos, Gria3, Htr1a, Id1, Id3, Il6ra, Jun, Nr2f2, Nr4a1, Plat, Pnoc,
Rxra, Sp1, Stat1
Mode 2 Drd2, Sst
Datasets were sorted by the administered drug and brain region. Gene expression values for each time point (0, 1, 3, 7, 14, and 21 days) were
arranged into a time series specific for each treatment type (repeated and acute). Genes for which the expression profiles over time most closely
approximated the global expression (SVD modes) are listed for DMI (top) and CIT (bottom) treatment
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Table 2 Functional GO classes and TFBSs over-representation in groups of genes associated with time-dependent changes in expression after the
DMI (top) and CIT (bottom) treatments
Region GO TFBS over-representation
GO term Fold changes
(p value)





3.36 (0.007) Pax4 (MA0068) PAIRED-HOMEO 10.1 (0.0000)
GO:0005216~ion channel activity 3.36 (0.022) MEF2A (MA0052) MADS 5.2 (0.0223)
GO:0005624~membrane fraction 2.14 (0.026) SRF (MA0083) MADS 4.9 (0.0317)
GO:0016021~integral to membrane 1.51 (0.039)
GO:0007610~behavior 1.64 (0.049)
CCX MEF2A (MA0052) MADS 5.6 (0.0037)
Pax5 (MA0014) PAIRED 5.6 (0.004)
SRF (MA0083) MADS 5.4 (0.0055)
ESR1 (MA0112) NUCLEAR RECEPTOR 4.6 (0.0254)
FOXF2 (MA0030) FORKHEAD 4.3 (0.0357)
CEBPA (MA0102) bZIP 4.2 (0.0452)
HIP GO:0043234~protein complex 1.77 (0.002) MEF2A (MA0052) MADS 4.9 (0.0053)
GO:0022857~transmembrane
transporter activity
2.71 (0.007) CREB1 (MA0018) bZIP 4.9 (0.0055)
GO:0046983~protein dimerization
activity
1.86 (0.015) SRF (MA0083) MADS 4.6 (0.0095)
GO:0015075~ion transmembrane
transporter activity






1.85 (0.001) SRF (MA0083) MADS 5.4 (0.0028)
GO:0004872~receptor activity 1.68 (0.002) Pax5 (MA0014) PAIRED 4.8 (0.0091)
GO:0016021~integral to membrane 1.70 (0.002) CREB1 (MA0018) bZIP 4.5 (0.0161)
GO:0004871~signal transducer activity 1.52 (0.005) MEF2A (MA0052) MADS 3.9 (0.0484)
GO:0051240~positive regulation
of multicellular organismal process
1.83 (0.029)
GO:0007610~behavior 1.60 (0.043)
GO:0050896~response to stimulus 1.24 (0.047)
Citalopram
PCX SRF (MA0083) MADS 7.1 (0.0005)
MEF2A (MA0052) MADS 5.1 (0.0191)
Pax4 (MA0068) PAIRED-HOMEO 4.9 (0.0232)
CREB1 (MA0018) bZIP 4.9 (0.0234)
CCX SRF (MA0083) MADS 5.6 (0.0066)
CREB1 (MA0018) bZIP 4.9 (0.0223)
Pax5 (MA0014) PAIRED 4.8 (0.026)
MEF2A (MA0052) MADS 4.7 (0.0289)
HIP GO:0043234~protein complex 1.52 (0.002) Pax4 (MA0068) PAIRED-HOMEO 4.7 (0.0038)
GO:0043170~macromolecule
metabolic process
1.27 (0.007) SRF (MA0083) MADS 4.1 (0.0165)
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whereas the expression level was constant for the single-dose
treatment. CIT induced entirely different changes in the ex-
pression of Fos and Nr4a1, e.g., the significant increases in
the mRNA levels for these genes in the CCX and almost no
differences between time-courses in gene expression after
repeated and acute treatment were observed. In the CCX,
HIP, and AMY, there was a peak in gene expression on day 3.
Not all of the changes in the expression profiles presented
in Fig. 3 are described in detail, they were meant only to show
that the changes in expression for a subset of individual genes
(which reached the statistical threshold of significance) oc-
curred at different time points. Some of the profiles were
similar when comparing the repeated and single-dose treat-
ments or brain regions, while others differed.
Evaluation of Egr1, c-fos, Nr4a1, and Id1 mRNA levels
by an in situ hybridization
As a second, independent analysis of gene expression changes
induced by AD treatment, we used in situ hybridization (ISH)
to compare the regulation of genes with the most pronounced
changes after CIT treatment. ISH also allowed us to evaluate
potential changes in other brain areas. The mRNA encoding
Egr1, c-fos, Nr4a1, and Id1 was measured in the CIT-treated
animals. Since the fold change of expression after CIT treat-
ment were the most significant in CCX after 3 days, this brain
region was selected for quantification at that specific time
point to validate changes obtained in RT-PCR experiments.
A modest but consistent increase (~20 %) in mRNA encoding
Egr1, Nr4a1, and c-fos was observed after 3 days of repeated
treatment in CCX. Overall two-way ANOVA (factors: time/
treatment) revealed significant effect of time on Egr1 (F1,220
5.42, p00.0295) and c-fos (F1,14011.51, p00.004) mRNA
level. In case of Nr4a1 (F1,2103.52, p00.0746) and Id1
(F1,1202.67, p00.1283), the effect of time on mRNA level
did not reach the level of significance, although in both cases,
the increase after 3 days of repeated treatment was observed
(Fig. 4).
Discussion
Studies based on microarray analyses of gene expression
following antidepressant treatment usually compare region-
specific gene expression changes either after different ADs
treatment (Altar et al. 2004; Boehm et al. 2006; Conti et al.
2007; Drigues et al. 2003; Jungke et al. 2011; Knuuttila et al.
2004; Palotas et al. 2004; Ploski et al. 2006; Sillaber et al.
2008; Takahashi et al. 2006; Wong et al. 2004) or in different
animal models of depression (Andrus et al. 2010; Bergstrom
et al. 2007; Orsetti et al. 2008; Surget et al. 2009). In our study,
we broadened the perspective by evaluating the time-course
of gene expression changes during antidepressant treatment.
Additionally, in our study, we applied RT-PCR arrays which
have significant advantages in specificity and sensitivity com-
pared with whole-genome cDNA microarrays whose results
may often be ambiguous due to technical reasons (Ostrowski
and Wyrwicz 2009).
The present study indicates that two ADs of different
pharmacological profiles influenced the expression of dif-
ferent genes, although some common changes induced by
these drugs were also observed. For the DMI treatment,
Table 2 (continued)
Region GO TFBS over-representation
GO term Fold changes
(p value)









AMY MEF2A (MA0052) MADS 11.7 (0.0000)
CREB1 (MA0018) bZIP 6.1 (0.0195)
NFKB1 (MA0105) REL 5.7 (0.0281)
SRF (MA0083) MADS 5.5 (0.0371)
ESR1 (MA0112) NUCLEAR RECEPTOR 5.2 (0.0474)
The statistical significance of GO enrichment for the time-dependent changes in gene expression was computed using algorithms implemented in
the DAVID 2008 database. The analyses were performed on lists of genes that correspond to changes in gene expression that reached the level of
statistical significance after two-way ANOVA for the time factor. An empty chart report means that there were no annotations that passed the
specified threshold (maximum EASE score, 0.05). For TFBS searches, the cREMaG software was used. The fold change of the detected number of
identified TFBSs compared to the number expected by chance and the statistical significance of the over-representation of the TFBS-containing
genes compared to the number expected by chance were computed using a z score test
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there was more similarity in the inter-region comparison
than in the inter-drug comparison of the same brain
structures.
Recently, Lee et al. (2010) studied the effects of three ADs
in different time points (1, 3, and 7 days) in the hippocampus.
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Fig. 3 Individual gene
expression profiles for some
transcription factors after (a)
DMI and (b) CIT treatments.
Values represent the relative
transcript levels (±SEM). Solid
line repeated treatment, dashed
line single-dose treatment. For
the lists of genes with signifi-
cant changes in expression es-
timated by ANOVA according
to the time factor, the treatment
type factor, or the interaction
between the two factors, see the
Venn diagrams (Fig. 2). *p<
0.05, **p<0.01 vs control; #p<
0.05 difference between repeat-
ed and single-dose treatments
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duration have not been clearly identified, although some of the
alterations reported were also observed in our study, i.e.,
Arrb1, Cdk5, Sst, and Jund. Changes in the expression of
Hspb1, c-fos, Crhbp, Egr1, Npy, glutamate ionotropic recep-
tors, Pax6, and members of the ATPase Ca2+ transporter
family observed in our study were also reported by Conti et
al. (2007) following electroconvulsive shock (ECS), sleep
deprivation, and fluoxetine.
Some evidence for the importance of ion transport in the
rat brain cortex have been reported in the context of antide-
pressant treatment (Knuuttila et al. 2004; Palotas et al.
2004). Specifically, changes in calcium channels (Cacna
and Cacnb) and voltage-gated sodium channels (Scn11a)
were observed after 28 days of treatment with amitryptiline
(Boehm et al. 2006). In the present study, a change in
Gria1–3, Scn2a1, and Cacna1a gene expression also oc-
curred. Gria1 and Gria3 encode the subunits GLUR1 and
GLUR3 of the glutamate ionotropic receptor (AMPA),
which are implicated in the mechanism of action of ADs
(Ampuero et al. 2010; Du et al. 2004; Knuuttila et al. 2004;
Martinez-Turrillas et al. 2002).
The important feature of ADs treatment is the delayed
onset of therapeutic effects (Machado-Vieira et al. 2010).
However, some reports indicate that treatment with selective
serotonin reuptake inhibitors (SSRIs) is associated with
symptomatic improvement by the end of the first week or
even as quickly as within the first 3 days of treatment (Taylor
et al. 2006; Mitchell 2006; Katz et al. 2004). These clinical
observations could reflect changes on the molecular level
shortly after the initiation of therapy. The results of the
present study clearly showed that expression changes of most
affected genes occurred in the first 3 days of treatment after
both drugs. Such immediate changes in gene expression were
apparent not only when individual genes were analyzed but
also in a global view of gene expression in the SVD diagrams.
The observed gene expression patterns were highly dynamic,
with oscillations and peaks occurring at different time points.
Such temporal fluctuations during ADs treatment may be a
reason for the discrepancies of results available from the
literature which were often obtained at different time points
of treatment. DMI, which influences noradrenaline reuptake,
is known to change the expression of mRNA encoding the
noradrenaline transporter in the rat locus ceruleus in a biphas-
ic manner with a decrease after 7 days and an increase after
14 days of treatment (Zhu et al. 2002). Such biphasic changes
are also seen for SSRI treatment of rats, with a temporary
reduction of serotonin transporter mRNA after 7 days but not
21 days of treatment with fluoxetine (Neumaier et al. 1996).
Additionally, changes in other cellular components (not di-
rectly linked to the monoamine reuptake inhibition) are also
described by time-dependent fluctuations of either mRNA or
protein levels. For example, the level of the glutamate iono-
tropic receptor GRIA2/3 reaches a peak after 7 and 21 days,
but not 14 days, of treatment with DMI (Martinez-Turrillas et
al. 2002), and the levels of the transcription factor AP-2 and
its DNA-binding activity are decreased after 7 days, but not
21 days, of treatment with CIT (Berggard et al. 2003). There
is also upregulation of glucocorticoid receptor in the hippo-
campus by 2 and 14 days, but not 7 days, exposure to tricyclic
antidepressants (Okugawa et al. 1999). Expression of BDNF
after ADs is another example: the significant decrease in
expression occurs after 4 days of fluoxetine, while chronic
administration of ADs induces increased BDNF expression
(de Foubert et al. 2004).
From these data, it is clear that dependence of various
measures on the duration of ADs treatment has already been
noticed, however, not dwelled upon any further, especially
in the context of any compensatory adaptations.
Analyses performed in the present work indicated an inter-
esting pattern of expression of immediate early genes (IEGs:
c-fos, Egr1, andNr4a1).Egr1 (also known as zif268,Krox-24,
and NGFI-A) has been extensively used as a marker of neu-
ronal responses to sensory stimuli. Despite the fact that
changes in the expression of c-fos and Egr1 are both consid-
ered to reflect neuronal activity, their expression patterns after
acute ADs treatment differ between brain regions (Slattery et
al. 2005), similar to our study. Chronic (6 or 9 days) ECS or
treatment with different ADs downregulate the induction of
a b c d
Fig. 4 Example images of Nr4a1 (a), Egr1 (b), c-fos (c) and Id1 (d)
mRNA expression as assessed by ISH (up) and quantification results
for mRNA expression of these genes in the CCX in groups treated for
3 days with CIT repeatedly and in a single dose (down). Data represent
the mean optical density±SEM (PSL/mm2) normalized to the control.
Student’s t test was used as post hoc test to compare the 3-day-treated
groups vs the control group; *p<0.05
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c-fos mRNA in response to acute restraint stress in rat frontal
cortex (Morinobu et al. 1995). A similar observation is made
for Egr1 after ECS or repeated tranylcypromine or imipramine
in PCX (Park et al. 2011). In our study, we also observed
downregulation of Egr1 and c-fos mRNA levels in PCX at
different time points during DMI treatment.
Another correlation observed in our study concerned the
expression profiles of c-fos and Nr4a1. Nr4a1 (NGFI-B,
Nur77) is a member of a subgroup of nuclear steroid recep-
tors that do not have any recognized ligands and function
independently as orphan receptors with transcriptional reg-
ulatory activity. Pharmacological studies indicate that
NGFI-B mRNA and protein levels are elevated via the
activation of adrenergic receptors (Humphries et al. 2004).
Evaluation of mRNA level by ISH in groups of animals
treated with CIT confirmed the upregulation of Egr1,
Nr4a1, and c-fos mRNA level after 3 days of repeated
treatment in the CCX. But the changes observed by ISH
were not so pronounced as evaluated by an RT-PCR meth-
od. The difference in mRNA fold change may reflect the
technical differences and sensitivity of these two methods
used to evaluate the gene expression. Additionally, both of
these methods are semiquantitative, so the most important is
the direction of observed changes, not the absolute value. In
gene expression studies, RT-PCR is the most sensitive meth-
od available, while ISH allows evaluating and visualizing
the localization of transcripts in various other brain regions
at the same time (Bartlett 2002), so they both can be con-
sidered as complementary.
As has been previously reported, the activation of IEGs,
associated with synaptic activity, learning, and memory, is
under the control of the SRF (Knoll and Nordheim 2009).
Interestingly, our analysis of TFBSs revealed an over-
representation of SRF binding sites in the promoters of
genes that changed over time after both the DMI and CIT
treatments in all brain regions. Also, binding sites for
MEF2A, which belongs with SRF to the MADS-box tran-
scription factors family, were over-represented. Although
these transcription factors have different DNA binding prop-
erties and are required for opposing cellular processes
(Schlesinger et al. 2011), an interaction between them has
been recently predicted by bioinformatics approaches and
confirmed experimentally (Pustylnik 2011).
One of the most interesting changes in gene expression
found in this study concerned the Dbp gene, which showed
a progressive decrease during repeated DMI treatment. The
D site of the albumin promoter (albumin D-box)-binding
protein, also known as DBP, belongs to the clock genes and
is expressed according to circadian rhythms (LopezMolina
et al. 1997). As sleep disturbances are common in major
depressive disorders and sleep deprivation is one possible
treatment for depression, Dbp may be involved in antide-
pressant action. Dbp has been already identified as a
potential candidate gene in bipolar disorder and alcoholism
by Niculescu and colleagues (Niculescu et al. 2000; Rodd et
al. 2007; Le-Niculescu et al. 2008). According to our pres-
ent study, Dbp may also be an interesting target for studies
on the mechanisms underlying antidepressant action.
Interestingly, the repeated and single-dose treatments
resulted in opposite regulation of the Id1 gene, which was
increased upon repeated DMI treatment. Id (inhibitor of
differentiation) functions as a negative regulator of differen-
tiation during development. ID1, together with ID2 and ID3,
increases the self-renewal and proliferation potential of the
cortical neural stem cells (Jung et al. 2010). In the present
study, we have shown, for the first time, alterations in Id1
expression after antidepressant treatment. Neuroplasticity is
believed to be involved in ADs action, so changes in Id1
gene expression in the brain cortex may be another
potential target for further studies concerning ADs and
depression.
In addition to the evaluation of temporal changes in gene
expression and comparison of the effects of two ADs, the
aim of our study was to verify the hypothesis that single-
dose treatment induces similar molecular changes to those
seen under repeated treatment. This hypothesis fits into the
idea of time-dependent sensitization (TDS) (Antelman and
Gershon 1998; Antelman et al. 2000) which assumes that
the therapeutic effects of a drug may not be due to the drug’s
action per se but they rather develop as a function of time. A
drug is viewed as a foreign substance and stressor that
induces a time-dependent cascade of molecular events, irre-
spective of whether it is given repeatedly or only once.
There are many pharmacological examples of TDS
(Antelman et al. 2000). In the case of ADs, the increased
level of monoamines at the synapse may only be an early
step in a potentially complex cascade of molecular events
that results in an AD’s therapeutic effects (Pineyro and Blier
1999). The results of the present study cannot definitely
confirm nor reject the hypothesis of TDS in ADs action.
Interestingly, the expression of most affected genes was
observed to change with time (time factor in a two-way
ANOVA) but not with the treatment type, especially after
CIT treatment. As described in the “Introduction” section,
the genes chosen for investigation in the present study are
either strongly believed, on the basis of available data, to be
involved in ADs action or are novel targets for new ADs
therapies. The changes in expression of many of these genes
did not show any significant difference between treatment
types (repeated or single-dose, followed by the same period
of time). This may confirm the role of time in ADs treatment
as more important than the role of the drug itself, although
the two drugs used in our study activated different molecular
processes and pathways, as revealed by our bioinformatics
analysis. On the other hand, if we discard the TDS hypoth-
esis, we have to question the role of many of the selected
Psychopharmacology (2012) 223:281–297 293
genes as true antidepressant targets since their expression
was altered irrespective of treatment type.
However, one might also consider the alterations in var-
ious gene expression induced by a single dose of a given
AD as compensatory mechanisms which are triggered in the
brain in response to external perturbing stimuli (e.g., drug
administration). One may also suppose that such mecha-
nisms are triggered each time the drug is administered,
resulting in complex, reciprocal interactions at many levels,
also in gene expression—therefore, different alterations are
observed at various time points.
The methodology employed here enables to detect very
subtle changes in gene expression, which is especially impor-
tant in neuroscience (Mirnics et al. 2001). Laser microdissec-
tion allowed the precise excision of the specified populations
of cells, and the RT-PCR arrays allowed us to investigate
many genes at once. Because gene expression levels were
measured in four regions of the same brains, inter-regional
comparisons of the expression profiles and the finding of
correlations between alterations in groups of genes and
interconnected brain regions were possible. Data on multiple
gene expression at sequential time points (0, 1, 3, 7, 14, and
21 days) were analyzed using SVD as a means to capture
dominant trends, called characteristic modes. In this way, the
data were represented by a small number of dominant modes
which capture many essential features of the time pattern in
gene expression. SVD analysis provided a global picture of
the dynamics of gene expression and enabled the comparison
of the expression of different genes across various brain
regions upon treatment with different ADs.
The expression patterns of the investigated genes
depended on the drug (DMI or CIT), drug treatment sched-
ule (repeated or acute), and the brain region studied, which
strongly indicate the specificity of the observed molecular
changes upon ADs treatment and confirm the biological
significance of our results. Some gene expression changes
were common to both drugs used, but finding a final com-
mon pathway influenced by these two ADs was not possi-
ble. Surprisingly, considerable periodic changes in the
expression levels of many genes correlated with different
time points in ADs treatment, which broadens our under-
standing of ADs mechanism of action.
Conclusions
In conclusion, our objective was to study the alterations of
gene expression with respect to time, antidepressant used,
and brain region. Appropriate genes (95) were not chosen
randomly but—as we clearly stated in the “Introduction”
section—the choice was based on the data already pub-
lished, indicating their either proved or alleged importance
for the mechanism of action of antidepressants. We decided
to measure alterations in their expression in the same exper-
iment in order to avoid any variables. What we have found
is the complex picture of changes in gene expression, the
picture which may help to understand discrepancies often
encountered in the literature dealing with AD action. The
main finding of our work is that the gene expression pattern
during ADs treatment is highly dynamic, with oscillations
and peaks occurring at different time points of treatment.
Additionally, our study revealed a number of novel potential
targets for antidepressant therapy, such as the Dbp and Id1
genes, that were not previously directly linked to antidepres-
sant action. We are strongly convinced that the time has
come to look at the mechanisms of action of ADs through a
broader window instead of sticking to any particular mea-
sure, as, e.g., one gene or one protein, and building new
hypothesis which will lead us to the next dead end.
A similar conclusion has been put forward recently by
Kessler et al. (2011), who have analyzed the results from
neuroimaging studies of depressed patients. Despite the great
effort, the outcome of these studies has been “a surprising
heterogeneity of results with the eventual lack of practical
conclusions.” The authors suggest novel approaches using
longitudinal designs of neuroimaging studies, i.e., to “take
various pictures over the course of treatment.” Our studies,
although preclinical, strongly support that view.
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